📌 Key Takeaways
- Topic: Silica Demand in 2026: Key Industries Driving Growth
- Keywords: Grace Syloid
- Published: 2026-11-20 07:06:19
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silica Powder Supplier Guide: How to Compare Grades, Quality and Pricing
- What Is Silica Powder? Types, Particle Sizes, Grades and Common Applications
- Magnetic particles were synthesized with an iron-containing coating. The model drugs were safranin O and hydrocortisone. The particles were functionalized with a bulky azo derivative to act as a gatekeeper and stop early leakage of the drug. In vitro release models have demonstrated that most of the drug is released only in the colon, as desired. This is owing to the reductive environment in the colon (the presence of the azoreductase enzyme), where the enzymatic degradation of the azo bond resulted in controlled release. In addition, in vivo pharmacokinetic studies were conducted in a rat model of induced colitis to test the effect of the magnetic field during therapy. The findings boosted when the rats wore a magnetic belt, which extended the retention time of the particles in the desired areas [ 75 ]. Zhang et al. presented a study in which magnetic silica nanoparticles (filled with sulforaphane) were developed for the treatment of myocardial infarction [ 38 ]. In mouse models, effective accumulation was observed in the infarcted zone after the application of an external magnetic field [ 33, 75 ]. These results show the potential of using magnetic particles with magnetic field guidance [ 33 ]. Radhakrishnan et al. developed a drug delivery system (DDS) loaded with carboplatin for targeted lung cancer therapy [ 63 ]. The DDS was core-shell mesoporous silica functionalized with folic acid. Initially, the drug loading capability of the functionalized carrier was more than twice as high per surface unit compared to the non-functionalized carrier due to the anchored -NH 2 groups. The drug release was sustained but limited (up to 36%) in the case of the functionalized particle, similarly to previous cases. This is most likely owing to the stronger interactions between the amine groups and the carboplatin. The amino-functionalized particles were further functionalized with folic acid to increase cellular uptake of the particles, demonstrating the potential of folic acid-targeted therapy [ 63, 65, 76 ]. Cancer cells typically overexpress folate receptors, resulting in folate-mediated internalization that preferentially targets these cells [ 63, 76 ]. This was demonstrated in a drug-mediated cytotoxicity analysis where amino- and folate-functionalized particles were evaluated and compared. Much greater cytotoxicity was observed in cells overexpressing folate receptors [ 63 ]. Similar research was carried out by Shirani et al., where folic acid functionalized MSNs were loaded with gemcitabine as a model drug, to investigate its potential in cancer treatment, while actively targeting cancer cells [ 70 ]. Outcomes have shown that higher cellular uptake (HeLa and K562 cells) was observed in the case of the functionalized particles, compared with the non-functionalized carriers [ 70 ]. Jafarpour et al. demonstrated the importance of functionalizing the carriers to accomplish targeted therapy utilizing methotrexate as a model drug [ 76 ]. The particles were grafted with a copolymer to act as a pH-responsive gatekeeper and folic acid to actively target cancer cells [ 76 ]. Ortiz et al. similarly designed a pH-responsive DDS, loaded with the anticancer drug doxorubicin [ 11 ]. The particles were functionalized with transferrin through a pH-sensitive linker as a gatekeeper, controlling the release kinetics and preventing early leakage of the drug [ 11 ]. An interesting breast cancer therapy was published by Mal et al. using doxorubicin as API and mesoporous silica as a carrier [ 65 ]. The amine-functionalized MSNs were PEGylated and then conjugated with folic acid or hyaluronic acid. It was also published that coating the nanoparticles with polydopamine (PDA) and polyethylene glycol (PEG) brings about prolonged doxorubicin release from MSNs [ 77 ]. These conjugates enabled ligand-mediated targeted drug delivery [ 65 ]. Researchers have developed a successful DDS that targets cancer cells, thus staying away from the side effects associated with doxorubicin in conventional cancer therapy. This is important because in vitro cytotoxicity studies have shown that the free drug has higher cytotoxicity than the nanocarriers [ 65 ]. Shahbaz et al. developed a redox-responsive silica nanocarrier loaded with paclitaxel to target breast cancer cells [ 67 ]. The amine-functionalized silica core was coated with disulfide-functionalized non-porous silica shell. Then the core-shell carriers were further coated with polyethylene glycol via disulfide linkages. In vitro drug release assay verified the correlation between the redox potential of the environment and the release kinetics. This is an important finding, as it has been revealed that cancer cells possess a higher redox ability than healthy cells. This provides controlled paclitaxel release for targeted therapy. According to cell uptake and cell viability assays, this DDS is noticeably more effective than free paclitaxel, making this nanocarrier an exciting prospect [ 67 ]. These illustrations highlight the importance of surface functionalization and employing stimuli-responsive gatekeepers to attain productive targeted therapy.
- Silica Aerogel Blanket: Thermal Conductivity, Thickness Options and Insulation Uses
- Is Silicon Dioxide Acidic or Basic? Its Acidic Oxide Behavior Explained
- In spite of the advantages of solvent-free processes, solvent-based techniques offer a more widespread choice for filling the pores of the carriers. Each method listed here consists of two steps. First, mixing the drug solution and carrier, then removing the solvent [ 36 ]. The loading cycles can be repeated as many times as desired to increase the charging efficiency [ 20, 36 ]. These techniques can be effectively applied to molecules both with great and poor aqueous solubility [ 37 ]. However, removing the solvent residue at the end of the process is essential, owing to the toxicity of usually used organic solvents [ 56 ], and it is normally better to select a less toxic organic solvent, if possible [ 37, 56 ]. The adsorption of the API is also influenced by the properties of the solvent, such as viscosity or surface tension. This group includes the adsorption approach, the incipient wetness approach, the solvent evaporation method, and the use of liquid and supercritical CO 2. The adsorption technique (solvent immersion method) is a low-energy process, but the pores can be filled effectively only if the API reaches a high concentration in the solvent [ 37 ]. The carrier system is immersed in the concentrated drug solution, while the liquid fills the pores owing to capillary forces. The mesopores are then separated from the solution by filtration or centrifugation. Finally, the pores are dried under reduced pressure [ 2, 36, 37 ]. Drug loading abilities can be seen for some APIs by this loading approach, in the following figure ( Figure 1 ). During the incipient wetness impregnation, a greatly concentrated drug solution is added dropwise onto the surface of the mesopores, in a nearly equal volume to the pore volume of the carrier [ 37 ]. In this case, the pores are filled with liquid also owing to the capillary forces. Then the pores are dried out at a higher temperature and under reduced pressure [ 2, 36, 37 ]. Nevertheless, the third approach, solvent evaporation, is the most widely used because it can be applied to a wide range of molecules, regardless of their solubility, making it fitting for higher therapeutic doses as well. It is not necessary to prepare a concentrated solution since the concentration gradually increases during the process (owing to the evaporation of the solvent). During the process, the drug should be dissolved in a volatile organic solvent, which is mixed with the carrier system [ 20 ]. All solvents are then eliminated by quick evaporation [ 37 ], while the drug is absorbed into the pores of the drug carrier [ 36, 37 ]. The use of supercritical CO 2 brings about more productive and deeper pore filling compared to other solvents. In this state, neither a liquid phase nor a gas phase exists. It combines the brilliant diffusion capacity of gases and the excellent solvation capacity of liquids. In addition, it is non-toxic, non-flammable, and can be readily eliminated from the system. A cost-effective choice can be liquid CO 2, which is a similarly effective solvent [ 36, 37 ].
- Silica Manufacturer in China: How to Evaluate Quality, Capacity and Export Experience
Silicon Dioxide CAS 7631-86-9: Identification, Properties and Regulatory Information
What is silica (SiO₂)?
high purity quartz market
What is the difference between fumed silica and precipitated silica?
quartz crucible sand
What drives silica raw material prices?
silica flatting agent Mesoporous silica nanoparticles (MSNs) are a flexible platform for the improvement of water solubility and bioavailability of poorly water-soluble drugs through the stabilization of the API in the amorphous state. Two outstanding mechanisms facilitate such stabilization: physical entrapment within nanoscale pores with a diameter less than the size of the critical nucleus. In this case, the ordered molecular packing necessary to develop crystals cannot advance. Moreover, the unique interactions between the functional groups of APIs and the surface silanol groups of MSNs may immobilize drug molecules at or close to pore walls [ 44, 45 ]. Bavnhøj et al. used celecoxib to demonstrate that when loading is conducted under the pore-filling ability (PFC) of the silica matrix, the drug will be physically stable and amorphous for at least 18 months of dry storage. PFC-loaded along with near-PFC-loaded samples recrystallized, especially upon exposure to moisture, demonstrating the razor-thin margin between the level of loading and stability [ 46 ]. Although advantages are present, long-term stability is undermined by stress recrystallization. For example, α-mangostin began to recrystallize after 7-14 days at 25 °C and 95% relative humidity in MSNs with slightly broader pore size than the molecular size of the API, indicating that pore size must be finely tuned for productive confinement [ 47 ]. Similarly, simvastatin had the longest amorphous lifespan when loaded into pores of 4.5 nm. Still, it exhibited rapid recrystallization in materials with bigger pore size, underlining the critical importance of pore size for the preservation of amorphous stability [ 45, 47 ].
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.